These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 8861178)

  • 21. Double-blind comparison of haloperidol decanoate and fluphenazine decanoate effectiveness, side-effects, dosage and serum levels during a six months' treatment for relapse prevention.
    Kissling W; Möller HJ; Walter K; Wittmann B; Krueger R; Trenk D
    Pharmacopsychiatry; 1985 May; 18(3):240-5. PubMed ID: 4011672
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Pharmaco-clinical correlations during fluoxetine administration in patients with depressive schizophrenia treated with haloperidol decanoate].
    Viala A; Aymard N; Leyris A; Caroli F
    Therapie; 1996; 51(1):19-25. PubMed ID: 8762216
    [TBL] [Abstract][Full Text] [Related]  

  • 23. D2 dopamine receptor occupancy during low-dose treatment with haloperidol decanoate.
    Nyberg S; Farde L; Halldin C; Dahl ML; Bertilsson L
    Am J Psychiatry; 1995 Feb; 152(2):173-8. PubMed ID: 7840348
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Haloperidol decanoate: a depot antipsychotic.
    Hemstrom CA; Evans RL; Lobeck FG
    Drug Intell Clin Pharm; 1988 Apr; 22(4):290-5. PubMed ID: 2897276
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A long-term cross-over pharmacokinetic study comparing perphenazine decanoate and haloperidol decanoate in schizophrenic patients.
    Dencker SJ; Giös I; Mårtensson E; Nordén T; Nyberg G; Persson R; Roman G; Stockman O; Svärd KO
    Psychopharmacology (Berl); 1994 Feb; 114(1):24-30. PubMed ID: 7846204
    [TBL] [Abstract][Full Text] [Related]  

  • 26. 19F-magnetic resonance spectroscopy and chemical shift imaging for schizophrenic patients using haloperidol decanoate.
    Sassa T; Suhara T; Ikehira H; Obata T; Girard F; Tanada S; Okubo Y
    Psychiatry Clin Neurosci; 2002 Dec; 56(6):637-42. PubMed ID: 12485307
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Evaluation of clinical usefulness of decaldol (haloperidol decanoate) produced by WZF Polfa in Warsaw in long-term treatment of schizophrenia].
    Morasiewicz J; Baranowski P; Borys J; Jańska-Skomorowska M; Kiejna A
    Psychiatr Pol; 1995; 29(3):405-20. PubMed ID: 7652093
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Duration of neuroleptic treatment and relapse rate: a 5-year follow-up study with haloperidol decanoate.
    Youssef HA
    Clin Neuropharmacol; 1991; 14 Suppl 2():S16-21; discussion S22-3. PubMed ID: 1684308
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Delayed normalization of central D2 dopamine receptor availability after discontinuation of haloperidol decanoate. Preliminary findings.
    Nyberg S; Farde L; Halldin C
    Arch Gen Psychiatry; 1997 Oct; 54(10):953-8. PubMed ID: 9337776
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Haloperidol decanoate: a depot neuroleptic.
    Drug Ther Bull; 1983 May; 21(10):39-40. PubMed ID: 6134606
    [No Abstract]   [Full Text] [Related]  

  • 31. Prolonged haloperidol and reduced haloperidol plasma concentrations after decanoate withdrawal.
    Chang WH; Lin SK; Juang DJ; Chen LC; Yang CH; Hu WH; Chien CP; Lam YW; Jann MW
    Schizophr Res; 1993 Mar; 9(1):35-40. PubMed ID: 8461270
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Clinical pharmacokinetics of haloperidol decanoate. Comparison with other prolonged-action neuroleptics].
    Levron JC; Ropert R
    Encephale; 1987; 13(2):83-7. PubMed ID: 2885172
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Long-term maintenance therapy with quetiapine versus haloperidol decanoate in patients with schizophrenia or schizoaffective disorder.
    Glick ID; Marder SR
    J Clin Psychiatry; 2005 May; 66(5):638-41. PubMed ID: 15889952
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Correlation between steady-state plasma concentrations (Css) of bromperidol and haloperidol.
    Yasui N; Otani K; Kondo T; Suzuki A; Furukori H; Kaneko S; Inoue Y
    Prog Neuropsychopharmacol Biol Psychiatry; 1998 Apr; 22(3):485-92. PubMed ID: 9612845
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Dosage strategies with long-acting injectable neuroleptics, including haloperidol decanoate.
    Kane JM
    J Clin Psychopharmacol; 1986 Feb; 6(1 Suppl):20S-23S. PubMed ID: 2870088
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharmacokinetics of haloperidol decanoate. A 2-year follow-up.
    Reyntigens AJ; Heykants JJ; Woestenborghs RJ; Gelders YG; Aerts TJ
    Int Pharmacopsychiatry; 1982; 17(4):238-46. PubMed ID: 7185768
    [TBL] [Abstract][Full Text] [Related]  

  • 37. An acute oral intoxication with haloperidol decanoate.
    Dekkers BGJ; Eck RJ; Ter Maaten JC; Touw DJ
    Am J Emerg Med; 2017 Sep; 35(9):1387.e1-1387.e2. PubMed ID: 28705742
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Minimal effective dose and relapse--double-blind trial: haloperidol decanoate vs. placebo.
    Eklund K; Forsman A
    Clin Neuropharmacol; 1991; 14 Suppl 2():S7-12; discussion S12-5. PubMed ID: 1684310
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Haloperidol decanoate in chronic schizophrenia: a study of 12 months with plasma levels.
    Altamura CA; Colacurcio F; Mauri MC; Moro AR; De Novellis F
    Prog Neuropsychopharmacol Biol Psychiatry; 1990; 14(1):25-35. PubMed ID: 1967847
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Quality of life of schizophrenic patients treated with haloperidol depot and injection preparation of long-lasting risperidone.
    Mihajlović G; Jovanović-Mihajlović N; Radmanović B; Radonjić K; Djukić-Dejanović S; Janković S; Janjić V; Milovanović N; Petrović D; Tomić K
    Srp Arh Celok Lek; 2011 Dec; 139 Suppl 1():36-40. PubMed ID: 22352201
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.